Biocompatibles Lens Unit Divestiture Could Ripen Firm For Abbott Purchase
This article was originally published in The Gray Sheet
Executive Summary
Biocompatibles' divestiture of its Eye Care division to Cooper Companies converts the British firm into a pure-play entity in the coronary and drug-coated stent market